Literature DB >> 19049583

Medium-chain triglyceride (MCT) ketogenic therapy.

Yeou-mei Christiana Liu1.   

Abstract

The medium-chain triglyceride diet (MCTD) is a variant of the classic 4:1 ketogenic diet (KD) introduced in 1971 by Huttenlocher as an attempt to improve the palatability of the KD by allowing more carbohydrates yet preserving ketosis. Although initially found to be equally effective as the classic KD, use of the MCTD declined because of frequent gastrointestinal side effects such as cramps, diarrhea, and vomiting. Recently, we have used the MCTD in more than 50 patients. We have found excellent seizure control, similar to the classic KD, and with careful monitoring, we have encountered minimal side effects. The MCTD should remain a viable dietary option for children with refractory epilepsy who have large appetites, can tolerate more calories, or cannot accept the restrictions of the classic KD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19049583     DOI: 10.1111/j.1528-1167.2008.01830.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  16 in total

Review 1.  The biochemistry of ketogenesis and its role in weight management, neurological disease and oxidative stress.

Authors:  Peter Andrew C McPherson; Jane McEneny
Journal:  J Physiol Biochem       Date:  2011-10-08       Impact factor: 4.158

2.  Ketogenic Diet Provides Neuroprotective Effects against Ischemic Stroke Neuronal Damages.

Authors:  Sheyda Shaafi; Javad Mahmoudi; Ali Pashapour; Mehdi Farhoudi; Saeed Sadigh-Eteghad; Hossein Akbari
Journal:  Adv Pharm Bull       Date:  2014-12-31

3.  An update on the ketogenic diet, 2012.

Authors:  Ayelet Halevy; Lilach Peleg-Weiss; Roni Cohen; Avinoam Shuper
Journal:  Rambam Maimonides Med J       Date:  2012-01-31

Review 4.  Potential Synergies of β-Hydroxybutyrate and Butyrate on the Modulation of Metabolism, Inflammation, Cognition, and General Health.

Authors:  Franco Cavaleri; Emran Bashar
Journal:  J Nutr Metab       Date:  2018-04-01

Review 5.  All You Need Is Fats-for Seizure Control: Using Amoeba to Advance Epilepsy Research.

Authors:  Eleanor C Warren; Matthew C Walker; Robin S B Williams
Journal:  Front Cell Neurosci       Date:  2018-07-11       Impact factor: 5.505

6.  Tolerability and Safety of a Novel Ketogenic Ester, Bis-Hexanoyl (R)-1,3-Butanediol: A Randomized Controlled Trial in Healthy Adults.

Authors:  Oliver Chen; Traci M Blonquist; Eunice Mah; Kristen Sanoshy; Dawn Beckman; Kristin M Nieman; Barbara L Winters; Joshua C Anthony; Eric Verdin; John C Newman; Brianna J Stubbs
Journal:  Nutrients       Date:  2021-06-16       Impact factor: 5.717

7.  Seizure control by ketogenic diet-associated medium chain fatty acids.

Authors:  Pishan Chang; Nicole Terbach; Nick Plant; Philip E Chen; Matthew C Walker; Robin S B Williams
Journal:  Neuropharmacology       Date:  2012-11-20       Impact factor: 5.250

8.  Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology.

Authors:  Milene L Brownlow; Leif Benner; Dominic D'Agostino; Marcia N Gordon; Dave Morgan
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

9.  A randomised trial of a medium-chain TAG diet as treatment for dogs with idiopathic epilepsy.

Authors:  Tsz Hong Law; Emma S S Davies; Yuanlong Pan; Brian Zanghi; Elizabeth Want; Holger A Volk
Journal:  Br J Nutr       Date:  2015-09-04       Impact factor: 3.718

10.  Seizure control by decanoic acid through direct AMPA receptor inhibition.

Authors:  Pishan Chang; Katrin Augustin; Kim Boddum; Sophie Williams; Min Sun; John A Terschak; Jörg D Hardege; Philip E Chen; Matthew C Walker; Robin S B Williams
Journal:  Brain       Date:  2015-11-25       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.